Good Pharmacovigilance Practice in the United States and the European Union
The article presents the results of a comparative analysis of Goodpharmacovigilance practices (GVP), developed by experts of the regulatory bodiesof the European Union (EU) and the United States. It is shown that the EU GVP cover almost all possible aspects of pharmacovigilance. It is noted that the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2022-06-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/318 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849252364938117120 |
|---|---|
| author | V. A. Merkulov N. D. Bunyatyan A. P. Pereverzev |
| author_facet | V. A. Merkulov N. D. Bunyatyan A. P. Pereverzev |
| author_sort | V. A. Merkulov |
| collection | DOAJ |
| description | The article presents the results of a comparative analysis of Goodpharmacovigilance practices (GVP), developed by experts of the regulatory bodiesof the European Union (EU) and the United States. It is shown that the EU GVP cover almost all possible aspects of pharmacovigilance. It is noted that the disadvantages of EU GVP are difficulties in the correct understanding and interpretation of certain definitions and processes, as well as the complexity of the implementation in practice of a number of provisions, mainly related to the organization of the quality management system, including audit and inspection. As the basis for development of the Russian Rules GVP is recommended to use the GVP EU |
| format | Article |
| id | doaj-art-2e8d10becbd14d1ab34f58252937bf9f |
| institution | Kabale University |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| publishDate | 2022-06-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj-art-2e8d10becbd14d1ab34f58252937bf9f2025-08-20T03:56:38ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642022-06-01042328250Good Pharmacovigilance Practice in the United States and the European UnionV. A. Merkulov0N. D. Bunyatyan1A. P. Pereverzev2Scientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationThe article presents the results of a comparative analysis of Goodpharmacovigilance practices (GVP), developed by experts of the regulatory bodiesof the European Union (EU) and the United States. It is shown that the EU GVP cover almost all possible aspects of pharmacovigilance. It is noted that the disadvantages of EU GVP are difficulties in the correct understanding and interpretation of certain definitions and processes, as well as the complexity of the implementation in practice of a number of provisions, mainly related to the organization of the quality management system, including audit and inspection. As the basis for development of the Russian Rules GVP is recommended to use the GVP EUhttps://www.risksafety.ru/jour/article/view/318good pharmacovigilance practices, gvp, european union, eu, united states |
| spellingShingle | V. A. Merkulov N. D. Bunyatyan A. P. Pereverzev Good Pharmacovigilance Practice in the United States and the European Union Безопасность и риск фармакотерапии good pharmacovigilance practices, gvp, european union, eu, united states |
| title | Good Pharmacovigilance Practice in the United States and the European Union |
| title_full | Good Pharmacovigilance Practice in the United States and the European Union |
| title_fullStr | Good Pharmacovigilance Practice in the United States and the European Union |
| title_full_unstemmed | Good Pharmacovigilance Practice in the United States and the European Union |
| title_short | Good Pharmacovigilance Practice in the United States and the European Union |
| title_sort | good pharmacovigilance practice in the united states and the european union |
| topic | good pharmacovigilance practices, gvp, european union, eu, united states |
| url | https://www.risksafety.ru/jour/article/view/318 |
| work_keys_str_mv | AT vamerkulov goodpharmacovigilancepracticeintheunitedstatesandtheeuropeanunion AT ndbunyatyan goodpharmacovigilancepracticeintheunitedstatesandtheeuropeanunion AT appereverzev goodpharmacovigilancepracticeintheunitedstatesandtheeuropeanunion |